18385-77-8

Basic information

• Product Name: 6-Bromo-3,4-Dihydro-2H-1-Benzopyran-4-Ol
• Synonyms: 6-Bromo-3,4-Dihydro-2H-1-Benzopyran-4-Ol;6-bromochroman-4-ol;6-Bromo-3,4-Dihydro-2H-1-Benzopyran-4-Ol(WX633132)
• CAS NO: 18385-77-8
• Molecular Formula: C₉H₉BrO₂
• Molecular Weight: 229.07056
• Mol File: 18385-77-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Bromo-3,4-Dihydro-2H-1-Benzopyran-4-Ol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-3,4-Dihydro-2H-1-Benzopyran-4-Ol(18385-77-8)
• EPA Substance Registry System: 6-Bromo-3,4-Dihydro-2H-1-Benzopyran-4-Ol(18385-77-8)

Safety Data

• Hazardous Substances Data: 18385-77-8(Hazardous Substances Data)

Upstream product

• 49660-57-3 6-bromochroman-4-one 
• 3875-78-3 6-bromo-chroman 

Downstream Products

• 18385-87-0 6-bromo-2H-benzopyran 
• 70695-78-2 (3R,4S)-4-amino-6-bromochroman-3-ol 
• 1373215-42-9 4-fluoro-N-[(3R,4S)-3-hydroxy-6-piperazin-1-yl-chroman-4-yl]benzamide hydrochloride 
• 1373215-45-2 4-fluoro-N-((3R,4S)-3-hydroxy-6-(4-(oxetan-3-yl)piperazin-1-yl)chroman-4-yl)benzamide 
• 1373215-50-9 4-fluoro-N-((3R,4S)-3-hydroxy-6-(piperazin-1-yl)chroman-4-yl)benzamide 
• 1373215-15-6 (3R,4S)-4-(4-fluorobenzamido)-6-(4-(oxetan-3-yl)piperazin-1-yl)chroman-3-yl methylcarbamate 

Relevant articles and documents

Copper-Catalyzed C-H Fluorination/Functionalization Sequence Enabling Benzylic C-H Cross Coupling with Diverse Nucleophiles

Site-selective transformation of benzylic C-H bonds into diverse functional groups is achieved via Cu-catalyzed C-H fluorination with N-fluorobenzenesulfonimide (NFSI), followed by substitution of the resulting fluoride with various nucleophiles. The benzyl fluorides generated in these reactions are reactive electrophiles in the presence of hydrogen-bond donors or Lewis acids, allowing them to be used without isolation in C-O, C-N, and C-C coupling reactions.

Cathepsin S Inhibitor Compounds

The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable diluent or carrier. The present invention further provides methods for treating abdominal aortic aneurysm, plaque instability, atherosclerosis, or autoimmune disorders such as rheumatoid arthritis, psoriasis, and lupus comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS

In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such c